Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: A retrospective analysis of an anatolian society of medical oncology multicenter study

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1841-1844

  Inal, Ali ^a   Ciltas, Aydin ^b   Yildiz, Ramazan ^c   Berk, Veli ^d   Kos, F Tugba ^e   Dane, Faysal ^f   Unek, Ilkay Tugba ^g   Colak, Dilsen ^h   Ozdemir, Nuriye Yildirim ^e   Buyukberber, Suleyman ^b   Gumus, Mahmut ^c   Ozkan, Metin ^d   Isikdogan, Abdurrahman ^a  

^a DICLE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d ERCIYES UNIVERSITY   (Turkey)

^e ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cancer; Gemcitabin; Long term survivors; Pancreas; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; MORTALITY; ONCOLOGY; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVOR; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS;

EID: 84869472821     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1841     Document Type: Article

References (19)

1. Burris HA III, Moore MJ, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patient with advanced pancreas cancer: a randomised trial. J Clin Oncol, 15, 2403-13.
2. Colucci G, Giuliani F, Gebbia V, et al (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the gruppo oncologico dell'Italia Meridionale. Cancer, 94, 902-10.
3. Cooperman AM (2001). Pancreatic cancer: the bigger picture. Surg Clin North Am, 81, 557-74.
4. Engelken FJ, Bettschart V, Rahman MQ, et al (2003). Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 29, 368-73.
5. Goulart BH, Clark JW, Lauwers GY, et al (2009). Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol, 16, 2-13.
6. Heinemann V, Labianca R, Hinke A, et al (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol, 18, 1652-9.
7. Heinemann V, Quietzsch D, Gieseler F, et al (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol, 24, 3946-52.
8. Ikeda M, Okada S, Tokuuye K, et al (2001). Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer, 91, 490-5.
9. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 59, 225-49.
10. Maréchal R, Demols A, Gay F, et al (2007). Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology, 73, 41-51
11. Nakachi K, Furuse J, Ishii H, et al (2007). Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol, 37, 114-20.
12. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma version 2.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012
13. Papadoniou N, Kosmas C, Gennatas K, et al (2008). Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res, 28, 543-9.
14. Royal RE, Wolff RA, Crane CH (2011). Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancerprinciples and practice of oncology. 9th ed. Philadelphia: Lippincott and Wilkins, 2011, 61-989.
15. Ryan DP, Grossbard ML (1998). Pancreatic cancer:local success and distant failure. Oncologist, 3, 178-88.
16. Shimoda M, Katoh M, Kita J, et al (2010). The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy, 56, 501-6.
17. Ueno H, Okada S, Okusaka T, et al (2000): Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology, 59, 296-301.
18. Viret F, Ychou M, Lepille D, et al (2004). Gemcitabine in combination with cisplatin versus gemcitabine alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol, 22, 4118.
19. Yi JH, Lee J, Park SH, et al (2011). A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology, 80, 175-80.